Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 32, Number 6—June 2026

Research

Outbreak of Wickerhamomyces anomalus (formerly Candida pelliculosa) Bloodstream Infections, Venezuela, 2022–20231

Maribel Dolande-Franco2, Diego H. Caceres2Comments to Author , Juan F. Frey-Carrillo, Antoniellys Pérez-Guzmán, Andres Ceballos-Garzon, Aleiram Chaurio-Briceño, Bram Spruijtenburg, Yusely Roa-Díaz, Eelco F.J. Meijer, Elaine Cristina Francisco, Rodrigo Oliveira, Tatiana Drummond-Suinaga, and Jacques F. Meis
Author affiliation: Instituto Nacional de Higiene “Rafael Rangel,” Caracas, Venezuela (M. Dolande-Franco, J.F. Frey-Carrillo, A. Chaurio-Briceño); Immuno-Mycologics, Norman, Oklahoma, USA (D.H. Caceres); Universidad del Rosario, Bogota, Colombia (D.H. Caceres, A. Ceballos-Garzon); Radboudumc-CWZ Center of Expertise for Mycology, Nijmegen, the Netherlands (D.H. Caceres, B. Spruijtenburg, E.F.J. Meijer, J.F. Meis); Hospital Universitario de Caracas, Caracas (A. Pérez-Guzmán, Y. Roa-Díaz, T. Drummond-Suinaga); Canisius-Wilhelmina Hospital/Dicoon, Nijmegen (B. Spruijtenburg, E.F.J. Meijer); Universidade Federal de São Paulo, São Paulo, Brazil (E.C. Francisco); Antimicrobial Resistance Institute of São Paulo, São Paulo (E.C. Francisco); Universidade Federal do Paraná, Curitiba, Brazil (E.C. Francisco); Bruker Daltonics GmbH & Co., Bremen, Germany (R. Oliveira); University of Cologne, Cologne, Germany (J.F. Meis)

Main Article

Table

In vitro antifungal susceptibility testing metrics of 99 Wickerhamomyces anomalus isolates in study of outbreak of W. anomalus (formerly Candida pelliculosa) bloodstream infections, Venezuela, 2022–2023*

Antifungal Range Geometric mean MIC50 MIC90
Amphotericin B 0.063–0.25 0.077 0.063 0.125
Fluconazole 1–8 1.99 2 2
Itraconazole 0.031–0.25 0.068 0.063 0.125
Voriconazole 0.031–0.25 0.064 0.063 0.125
Posaconazole 0.031–0.25 0.059 0.063 0.063
Isavuconazole 0.016–0.125 0.029 0.031 0.063
Anidulafungin ≤0.008–0.031 0.01 ≤0.008 0.016
Micafungin ≤0.008–0.063 0.012 ≤0.008 0.031

*Values are µg/mL. In vitro antifungal susceptibility testing was conducted using the Clinical and Laboratory Standards Institute M27 broth microdilution (17). MIC50, MIC that inhibits 50% of isolates; MIC90, MIC that inhibits 90% of isolates.

Main Article

References
  1. Zhang  L, Xiao  M, Arastehfar  A, Ilkit  M, Zou  J, Deng  Y, et al. Investigation of the emerging nosocomial Wickerhamomyces anomalus infections at a Chinese tertiary teaching hospital and a systemic review: clinical manifestations, risk factors, treatment, outcomes, and anti-fungal susceptibility. Front Microbiol. 2021;12:744502. DOIPubMedGoogle Scholar
  2. Kurtzman  CP. Wickerhamomyces Kurtzman, Robnett & Basehoar-Powers (2008). In: Kurtzman CP, Fell JW, Boekhout T, editors. The yeasts, 5th edition. London: Elsevier; 2011. p. 899–917.
  3. Zhang  Z, Cao  Y, Li  Y, Chen  X, Ding  C, Liu  Y. Risk factors and biofilm formation analyses of hospital-acquired infection of Candida pelliculosa in a neonatal intensive care unit. BMC Infect Dis. 2021;21:620. DOIPubMedGoogle Scholar
  4. Chakrabarti  A, Singh  K, Narang  A, Singhi  S, Batra  R, Rao  KL, et al. Outbreak of Pichia anomala infection in the pediatric service of a tertiary-care center in Northern India. J Clin Microbiol. 2001;39:1702–6. DOIPubMedGoogle Scholar
  5. Rattani  S, Farooqi  J, Hussain  AS, Jabeen  K. Spectrum and antifungal resistance of candidemia in neonates with early- and late-onset sepsis in Pakistan. Pediatr Infect Dis J. 2021;40:814–20. DOIPubMedGoogle Scholar
  6. da Silva  CM, de Carvalho Parahym  AM, Leão  MP, de Oliveira  NT, de Jesus Machado Amorim  R, Neves  RP. Fungemia by Candida pelliculosa (Pichia anomala) in a neonatal intensive care unit: a possible clonal origin. Mycopathologia. 2013;175:175–9. DOIPubMedGoogle Scholar
  7. Lin  HC, Lin  HY, Su  BH, Ho  MW, Ho  CM, Lee  CY, et al. Reporting an outbreak of Candida pelliculosa fungemia in a neonatal intensive care unit. J Microbiol Immunol Infect. 2013;46:456–62. DOIPubMedGoogle Scholar
  8. Aragão  PA, Oshiro  IC, Manrique  EI, Gomes  CC, Matsuo  LL, Leone  C, et al.; IRIS Study Group. Pichia anomala outbreak in a nursery: exogenous source? Pediatr Infect Dis J. 2001;20:843–8. DOIPubMedGoogle Scholar
  9. Jung  J, Moon  YS, Yoo  JA, Lim  JH, Jeong  J, Jun  JB. Investigation of a nosocomial outbreak of fungemia caused by Candida pelliculosa (Pichia anomala) in a Korean tertiary care center. J Microbiol Immunol Infect. 2018;51:794–801. DOIPubMedGoogle Scholar
  10. Ratcliffe  L, Davies  J, Anson  J, Hales  S, Beeching  NJ, Beadsworth  MB. Candida pelliculosa meningitis as an opportunistic infection in HIV: the first reported case. Int J STD AIDS. 2011;22:54–6. DOIPubMedGoogle Scholar
  11. Ioannou  P, Baliou  S, Kofteridis  DP. Fungemia by Wickerhamomyces anomalus—a narrative review. Pathogens. 2024;13:269. DOIPubMedGoogle Scholar
  12. Park  KA, Ahn  K, Chung  ES, Chung  TY. Pichia anomala fungal keratitis. Cornea. 2008;27:619–20. DOIPubMedGoogle Scholar
  13. Sharma  M, Chakrabarti  A. Candidiasis and other emerging yeasts. Curr Fungal Infect Rep. 2023;17:15–24. DOIPubMedGoogle Scholar
  14. Spruijtenburg  B, Rudramurthy  SM, Meijer  EFJ, van Haren  MHI, Kaur  H, Chakrabarti  A, et al. Application of novel short tandem repeat typing for Wickerhamomyces anomalus reveals simultaneous outbreaks within a single hospital. Microorganisms. 2023;11:1525. DOIPubMedGoogle Scholar
  15. Spruijtenburg  B, Meis  JF, Verweij  PE, de Groot  T, Meijer  EFJ. Short tandem repeat genotyping of medically important fungi: a comprehensive review of a powerful tool with extensive future potential. Mycopathologia. 2024;189:72. DOIPubMedGoogle Scholar
  16. Spruijtenburg  B, van Haren  MHI, Chowdhary  A, Meis  JF, de Groot  T. Development and application of a short tandem repeat multiplex typing assay for Candida tropicalis. Microbiol Spectr. 2023;11:e0461822. DOIPubMedGoogle Scholar
  17. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts, 4th edition. CLSI standard M27. Wayne (PA): The Institute; 2017.
  18. Clinical and Laboratory Standards Institute. Epidemiological cutoff values for antifungal susceptibility testing, 4th edition. CLSI standard M57S. Wayne (PA): The Institute; 2022.
  19. Pasqualotto  AC, Sukiennik  TC, Severo  LC, de Amorim  CS, Colombo  AL. An outbreak of Pichia anomala fungemia in a Brazilian pediatric intensive care unit. Infect Control Hosp Epidemiol. 2005;26:553–8. DOIPubMedGoogle Scholar
  20. Francisco  EC, Caceres  DH, Brunelli  JGP, Garcia-Effron  G, Arastehfar  A, Ribeiro  FC, et al. An update on clinically relevant, rare, and emerging Candida and Saccharomycotina yeasts that have been recently reclassified from Candida. Clin Microbiol Rev. 2025;38:e0006423. DOIPubMedGoogle Scholar
  21. Yang  Y, Wu  W, Ding  L, Yang  L, Su  J, Wu  B. Two different clones of Candida pelliculosa bloodstream infection in a tertiary neonatal intensive care unit. J Infect Dev Ctries. 2021;15:870–6. DOIPubMedGoogle Scholar
  22. Turan  D, Habip  Z, Odabaşı  H, Dömbekçi  E, Gündoğuş  N, Özmen  M, et al. Antifungal susceptibilities of rare yeast isolates. J Fungi (Basel). 2025;11:645. DOIPubMedGoogle Scholar
  23. Astvad  KMT, Arikan-Akdagli  S, Arendrup  MC. A pragmatic approach to susceptibility classification of yeasts without EUCAST clinical breakpoints. J Fungi (Basel). 2022;8:141. DOIPubMedGoogle Scholar
  24. Verma  S, Tilak  R, Singh  G, Singh  S, Kumari  A, Rudramurthy  SM, et al. Multicentre investigation of Wickerhamomyces anomalus fungemia in India: emerging resistance and mechanistic insights. J Antimicrob Chemother. 2026;81:dkaf420. DOIPubMedGoogle Scholar
  25. Luo  Z, Ning  Y, Dai  R, Ainiwaer  A, Li  Y, Zhang  R, et al. A pan-azole and pan-echinocandin resistant Wickerhamomyces anomalus isolate causing bloodstream infection: ERG11Y140F, K151R with copy number variation and FKS1F665S mutation. Int J Med Microbiol. 2025;321:151689. DOIPubMedGoogle Scholar
  26. Luo  Z, Ning  Y, Xiao  M, Guo  D, Xu  H, Liu  Y, et al. High azole non-wild type rates and nosocomial microsatellite typing aggregation of Wickerhamomyces anomalus in China according to a 12-year multicenter surveillance study. J Antimicrob Chemother. 2025;80:1964–71. DOIPubMedGoogle Scholar

Main Article

1Preliminary results from this study were presented at the 22nd INFOCUS Conference; November 20–23, 2024; Bogota, Colombia.

2These authors share first authorship of this article.

Page created: April 17, 2026
Page updated: May 26, 2026
Page reviewed: May 26, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external